pentobarbital will lower the extent or effect of ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Robust CYP3A4 inducers may minimize partiaprevir and ritonavir concentrations, and thus reduced efficacy of Viekira Pak

pentobarbital will decrease the level or effect of disopyramide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Mysterious.

펜토바르비탈은 라이 증후군의 두개내의 압력을 줄이기 위해 사용되며, 또한 대뇌 빈혈환자의 뇌 손상을 줄이고, 뇌사를 낮추기 위해 사용된다.

pentobarbital will lower the extent or effect of dapsone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unidentified.

pentobarbital will lessen the level or result of tamoxifen by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

Contraindicated (one)pentobarbital will reduce the level or impact of roflumilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

By clicking mail, you acknowledge you have permission to e-mail the receiver with this data.

pentobarbital will lessen the level or effect of finasteride by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Mysterious.

Too rapid administration may perhaps trigger respiratory despair, laryngospasm, apnea, or vasodilation with fall in blood pressure level

pentobarbital will reduce the extent or impact of doravirine by influencing hepatic/intestinal enzyme CYP3A4 metabolism.

Contraindicated (1)pentobarbital will decrease the level or influence of cariprazine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. CYP3A4 is responsible for the formation and elimination of cariprazine's active metabolites.

pentobarbital will minimize the level or effect of repaglinide by impacting hepatic/intestinal enzyme CYP3A4 here metabolism. Use Caution/Keep an eye on.

Stay away from; coadministration with CYP3A inducers could result in lessened plasma concentrations of elvitegravir and/or maybe a concomitantly administered protease inhibitor and cause loss of therapeutic effect and also to attainable resistance

pentobarbital will reduce the level or result of lorlatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.